Literature DB >> 21441311

Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression.

Julie Favre1, Ji Gao, An Di Zhang, Isabelle Remy-Jouet, Antoine Ouvrard-Pascaud, Brigitte Dautreaux, Brigitte Escoubet, Christian Thuillez, Frédéric Jaisser, Vincent Richard.   

Abstract

The deleterious effects of aldosterone excess demonstrated in cardiovascular diseases might be linked in part to coronary vascular dysfunction. However, whether such vascular dysfunction is a cause or a consequence of the changes occurring in the cardiomyocytes is unclear. Moreover, the possible link between mineralocorticoid receptor (MR)-mediated effects on the cardiomyocyte and the coronary arteries is unknown. Thus we used a mouse model with conditional, cardiomyocyte-specific overexpression of human MR (hMR) and observed the effects on endothelial function in isolated coronary segments. hMR overexpression decreased the nitric oxide (NO)-mediated relaxing responses to acetylcholine in coronary arteries (but not in peripheral arteries), and this was prevented by a 1-mo treatment either with an MR antagonist, vitamin E/vitamin C, or a NADPH oxidase inhibitor. hMR overexpression did not affect coronary endothelial NO synthase content nor its level of phosphorylation on serine 1177, but increased cardiac levels of reactive oxygen species, cardiac NADPH oxidase (NOX) activity, and expression of the NOX subunit gp91phox, which was limited to endothelial cells. Thus an increase in hMR activation, restricted to cardiomyocytes, is sufficient to induce a severe coronary endothelial dysfunction. We suggest a new paracrine mechanism by which cardiomyocytes trigger a NOX-dependent, reactive oxygen species-mediated coronary endothelial dysfunction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21441311     DOI: 10.1152/ajpheart.00552.2010

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  17 in total

1.  Endothelial sodium channel activation promotes cardiac stiffness and diastolic dysfunction in Western diet fed female mice.

Authors:  James R Sowers; Javad Habibi; Guanghong Jia; Brian Bostick; Camila Manrique-Acevedo; Guido Lastra; Yan Yang; Dongqing Chen; Zhe Sun; Timothy L Domeier; William Durante; Adam T Whaley-Connell; Michael A Hill; Frederic Jaisser; Vincent G DeMarco; Annayya R Aroor
Journal:  Metabolism       Date:  2020-04-07       Impact factor: 8.694

Review 2.  Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation.

Authors:  Kathleen V Barrett; Amy T McCurley; Iris Z Jaffe
Journal:  Clin Exp Pharmacol Physiol       Date:  2013-12       Impact factor: 2.557

Review 3.  Aldosterone and cardiovascular disease: the heart of the matter.

Authors:  B Julie He; Mark E Anderson
Journal:  Trends Endocrinol Metab       Date:  2012-10-03       Impact factor: 12.015

Review 4.  The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series).

Authors:  Bradley A Maron; Jane A Leopold
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

5.  Aldosterone-Induced Vascular Remodeling and Endothelial Dysfunction Require Functional Angiotensin Type 1a Receptors.

Authors:  Marie Briet; Tlili Barhoumi; Muhammad Oneeb Rehman Mian; Suellen C Coelho; Sofiane Ouerd; Yohann Rautureau; Thomas M Coffman; Pierre Paradis; Ernesto L Schiffrin
Journal:  Hypertension       Date:  2016-04-04       Impact factor: 10.190

6.  Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.

Authors:  Luis M Ruilope; Rajiv Agarwal; Stefan D Anker; George L Bakris; Gerasimos Filippatos; Christina Nowack; Peter Kolkhof; Amer Joseph; Nicole Mentenich; Bertram Pitt
Journal:  Am J Nephrol       Date:  2019-10-30       Impact factor: 3.754

7.  Gene expression profiling of peripheral blood mononuclear cells in the setting of peripheral arterial disease.

Authors:  Rizwan Masud; Khader Shameer; Aparna Dhar; Keyue Ding; Iftikhar J Kullo
Journal:  J Clin Bioinforma       Date:  2012-03-12

Review 8.  Current status of NADPH oxidase research in cardiovascular pharmacology.

Authors:  Bruno K Rodiño-Janeiro; Beatriz Paradela-Dobarro; María Isabel Castiñeiras-Landeira; Sergio Raposeiras-Roubín; José R González-Juanatey; Ezequiel Alvarez
Journal:  Vasc Health Risk Manag       Date:  2013-07-25

Review 9.  Aldosterone and the heart: still an unresolved issue?

Authors:  Cristiana Catena; GianLuca Colussi; Francesca Nait; Flavia Martinis; Francesca Pezzutto; Leonardo A Sechi
Journal:  Front Endocrinol (Lausanne)       Date:  2014-10-14       Impact factor: 5.555

Review 10.  Alteration of energy substrates and ROS production in diabetic cardiomyopathy.

Authors:  O Lorenzo; E Ramírez; B Picatoste; J Egido; J Tuñón
Journal:  Mediators Inflamm       Date:  2013-10-31       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.